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Abstract
Pre-eclampsia (PE) complicates around 3% of all pregnancies and is one of the most com-
mon causes of maternal mortality worldwide. The pathophysiology of PE remains unclear
however its underlying cause originates from the placenta and manifests as raised blood
pressure, proteinuria, vascular or systemic inflammation and hypercoagulation in the
mother. Women who develop PE are also at significantly higher risk of subsequently devel-
oping cardiovascular (CV) disease. In PE, the failing endoplasmic reticulum, oxidative and
inflammatory stressed syncytiotrophoblast layer of the placenta sheds increased numbers
of syncytiotrophoblast extracellular vesicles (STBEV) into the maternal circulation. Platelet
reactivity, size and concentration are also known to be altered in some women who develop
PE, although the underlying reasons for this have not been determined. In this study we
show that STBEV from disease free placenta isolated ex vivo by dual placental perfusion
associate rapidly with platelets. We provide evidence that STBEV isolated from normal pla-
centas cause platelet activation and that this is increased with STBEV from PE pregnan-
cies. Furthermore, treatment of platelets with aspirin, currently prescribed for women at high
risk of PE to reduce platelet aggregation, also inhibits STBEV-induced reversible aggrega-
tion of washed platelets. Increased platelet reactivity as a result of exposure to PE placenta
derived STBEVs correlates with increased thrombotic risk associated with PE. These
observations establish a possible direct link between the clotting disturbances of PE and
dysfunction of the placenta, as well as the known increased risk of thromboembolism asso-
ciated with this condition.
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Introduction
Hypertensive disorders in pregnancy including pre-eclampsia (PE) are the commonest causes
of maternal mortality worldwide [1]. PE complicates around 3% of all pregnancies, with 10%
to 15% of maternal deaths directly linked to PE and eclampsia [2]. The underlying cause
remains unclear but it is known to be a placenta driven disorder often associated with poor pla-
cental perfusion and the subsequent release of factor(s) that trigger the maternal syndrome of
systemic inflammation, vascular endothelial dysfunction and platelet activation, which under-
lie the symptoms including increased blood pressure, proteinuria, inflammation and hypercoa-
gulation [3, 4]. Women with a diagnosis of hypertension or PE during pregnancy have now
been shown to have an increased risk of developing cardiovascular (CV) disease in the long-
term, including hypertension (3.7 (2.7–5.05)), ischemic heart disease (2.16 (1.86–2.52)), stroke
(1.81 (1.45–2.27)) and venous thromboembolism (1.79 (1.37–2.33) (relative risk (confidence
interval))[5]. Earlier detection of PE would present opportunities for more effective clinical
intervention with a significant impact on reducing levels of maternal and fetal morbidity, as
well as potentially improving long-term outcomes for women affected by PE and their
offspring.
Extracellular vesicles (EV) are shed from a variety of cells and have a number of important
physiological as well as pathological functions that have attracted increasing attention in vascu-
lar research. Indeed, EV originating from platelets, granulocytes, erythrocytes and endothelial
cells are associated with a variety of pathophysiological conditions including thrombosis and
inflammation. The cell type of origin, cellular activation and micro-environment in which EV
are generated is likely to determine their nature, composition and quantity [6]. It is now well
established that the placenta releases fetal-derived EVs into the maternal circulation during
normal pregnancy, and that this shedding is altered in PE [7–9]. EV are released from the syn-
cytiotrophoblast layer; which covers the surface of the placenta, directly into the maternal
bloodstream where they can potentially interact with the endothelium, circulating immune
cells and platelets. The release of these syncytiotrophoblast-derived EV (STBEV) in PE is ele-
vated compared to healthy pregnancies, [9–11] and the size, and the profile of proteins present
within STBEV in PE, is also significantly altered [9, 12].
It has been reported previously that platelets isolated from women that develop PE in the
latter stages of pregnancy display elevated cell surface levels of the platelet activation marker
CD63 and exhibit an increase in platelet-bound fibrinogen [13]. Furthermore, PE placentas
display a small but significant increase in the expression of the high affinity thrombin receptor
PAR1, while women with established PE display elevated STBEV tissue factor activity [14, 15].
It has been hypothesised that these changes may underlie the increased risk of arterial throm-
bosis during pregnancy and may be relevant to the increased lifetime risk of developing CV dis-
ease observed in women who have had PE. It is well established that increased platelet
reactivity and/or aberrant platelet activation play a central role in diseases of the CV system,
including atherosclerosis, stroke, and myocardial infarction [16]. HELLP syndrome (haemoly-
sis, elevated liver enzymes, low platelet count), a severe complication of PE associated with sys-
temic intravascular coagulation, also points to platelets as a major contributor to disease
pathophysiology.
Antiplatelet reagents, most often low dose aspirin, are prescribed to women at high risk of
developing PE and have been shown to reduce the relative risk of PE by 17% [17]. We hypothe-
sised that the interactions between STBEV and circulating platelets play a role in the increased
platelet reactivity and CV complications associated with PE, during both pregnancy and post-
partum. A better understanding of the role of STBEV in platelet activation and the mecha-
nism/s by which platelets are activated in this disease could lead to the development of more
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targeted therapeutics that selectively inhibit platelet signalling pathways activated in PE,
thereby increasing efficacy and decreasing side effects. The aim of this study therefore was to
investigate the effect of STBEV, isolated from PE and normal pregnancy derived placentas
using dual placental lobe perfusion, on several aspects of platelet function.
Materials and Methods
Placenta and Blood Donors and Reagents
Placentas, for isolation of STBEV were obtained from women with normal pregnancies (n = 3)
or PE (n = 4) undergoing caesarean section deliveries, within 10 min of delivery and were pro-
cessed immediately [9]. None of the women were in labour at the time of sampling, and all had
singleton pregnancies with no known fetal abnormalities (Table 1). Blood samples for platelet
isolation were collected from healthy non-pregnant female volunteers (n = 6) and were pro-
cessed immediately. These studies were approved by the Oxfordshire Research Ethics Commit-
tee C and informed written consent was obtained from all participants.
Isolation of STBEV by Ex Vivo Dual Placental Lobe Perfusion
STBEV were isolated using a modified dual placental perfusion system as described previously
[9, 18]. Briefly, an individual lobule was isolated and the fetal circulation component perfused
with filtered modified M-199 medium containing a bolus of streptokinase (100,000 IU) to pro-
mote clot removal, at a rate of 5mL/min. The whole placenta was then laid maternal side up
inside a Perspex water jacket maintained at 37°C. The maternal circulation was perfused with
37°C oxygenated media through eight 1.7mm fetal feeding tubes at a controlled rate of 20mL/
min. The lobule was perfused for 20min to equilibrate the system, after which time the mater-
nal circuit was closed with a total volume of 600mL perfusion medium. The volume of fetal
effluent was measured every 20min and the oxygen concentration of the maternal side perfus-
ate monitored to ensure the stability of the system. Pressure monitors were used to ensure no
significant deviations from baseline during the experimental period. At the end of the 3hr per-
fusion period, the maternal perfusate was centrifuged at 2x1500 xg for 10min at 4°C to remove
red blood cells and large cellular debris [19]. The supernatant was then removed and
Table 1. Details of the patients who donated placentas.
Patient Gestation (weeks
+days)
Parity Age
(years)
Maximum Systolic
(mmHg)
Maximum Diastolic
(mmHg)
Protein
(dipstick)
Birth Weight
(g)
Normal pregnant participants
N1 38+2 1+1 33 120 70 NAD 3110
N2 41+3 1+2 38 120 78 NAD 4156
N3 38+1 1+0 33 110 50 NAD 3405
Average 39+3 34.67 120 66 3557
Preeclamptic participants
P1 33+0 2+1 31 205 155 3+ 1570
P2 33+3 0+0 30 190 120 2+ 1740
P3 36+0 0+1 23 178 100 3+ 2495
P4 39+2 1+0 44 150 96 2+ 3500
Average 35+4 32 180.75 117.75 2326.25
Note: STBEV preparation P2 was used for immunoblotting and aggregation in response to STBEV and collagen alone. P3 was used for aggregation at
8x108 platelets and for aggregation and activation in aspirinated platelets.
doi:10.1371/journal.pone.0142538.t001
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centrifuged at 150,000 xg for 1hr at 4°C to isolate an EV preparation highly enriched for
STBEV [9]. The resultant pellets were washed in phosphate-buffered saline (PBS) before being
pooled and re-suspended in PBS at a concentration of 5mg/mL protein, determined using a
Pierce BCA protein assay kit (Thermo Scientific, Illinois, USA). Aliquots of STBEV were stored
at −80°C. Typical STBEV yield was 25–50mg total protein. Flow cytometric analysis of EV pro-
duced by this method revealed>90% of vesicles expressed the syncytiotrophoblast specific
marker placental alkaline phosphatase (PLAP) and<2% were platelet derived [9]. For aggrega-
tion, immunoblotting, thrombus formation and clot retraction assays, three separate STBEV
preparations from either normal (N STBEV) or PE (PE STBEV) pregnancies were tested on
platelets prepared from at least three donors. Pooled STBEV samples were used for the flow
cytometry, electron microscopy and in vitro thrombus formation analyses.
Preparation of Human Platelets
Human platelets were prepared by differential centrifugation as described previously [20].
Briefly, whole blood, drawn into tubes containing acid citrate dextrose (ACD), was centrifuged
at 200 xg for 20min at room temperature to obtain platelet-rich-plasma (PRP). For washed
platelets, PRP was centrifuged for 10min at 1000 xg in the presence of prostacyclin (PGI2) and
the cells re-suspended in Tyrodes-HEPES buffer (134mM NaCl, 0.34mM Na2HPO4, 2.9mM
KCL, 12mMNaHCO3, 20mMHEPES, 5mM glucose, 1mMMgCl2, pH 7.3), to a density of
either 4 or 8x108 platelets/mL. Where required, PRP was incubated with 100μM acetylsalicylic
acid (aspirin) for 30min at 30°C before being processed as normal to prepare washed platelets
[21].
Flow Cytometric Analysis of STBEV Interaction with Platelets
Platelets were incubated with STBEV that were fluorescently labelled with BODIPY-maleimide
(BODIPY FL N-(2-aminoethyl)-maleimide; Life Technologies) to establish whether STBEV
interact with platelets. Briefly, a pool of N STBEV (300μL at 5mg/mL of protein) was incubated
with BODIPY-maleimide (0.2mM final concentration) for 15min at room temperature before
being washed with sterile PBS (2x). Washed platelets at 4×108 cells/mL were then gently mixed
with BODIPY-maleimide labelled STBEV (50μg/mL) or Tyrodes-HEPES buffer control at
30°C, then immediately stimulated with 0.5units/mL thrombin or Tyrodes-HEPES control.
Stimulation was stopped at 5sec, 90sec, 5min, 20min and 60min by addition of a 4-fold volume
of 4% paraformaldehyde in PBS. Fixed platelets were pelleted by centrifugation and resus-
pended in PBS before processing for flow cytometric analysis. As STBEV are positive for CD41
and CD63 (data not shown), only samples of platelets alone and platelets treated with thrombin
were labelled for CD41 (platelet marker) and CD63 (platelet activation marker) to be certain
that any positive signal was platelet derived. CD41 positive events were then used to set the
platelet gate and surface CD63 expression was used to confirm platelet activation in response
to thrombin. Fixed platelets were incubated for 10min at room temperature with Fc receptor
block (BD Biosciences, UK), prior to 20min incubation with anti CD41-PECy7 (1ug/mL;
Clone P2, Beckman Coulter) and anti CD63-APC (1μg/mL; Clone H5C6, Biolegend) or appro-
priate isotype controls. Analysis was carried out on a LSR-II flow cytometer (BD Biosciences,
UK). A platelet gate was set using CD41 positive events to exclude the smaller unbound
STBEV and debris and 10,000 events were collected. The percentage of CD63 and BODIPY-
maleimide positive STBEV events in the platelet gate was then recorded as a measure of platelet
activation and platelet bound STBEV respectively. Data were analysed using FACS DIVA soft-
ware (BD Biosciences, UK).
STBEV Effect on Platelet Function
PLOS ONE | DOI:10.1371/journal.pone.0142538 November 9, 2015 4 / 15
Transmission Electron Microscopy
To further investigate the nature of the interaction of STBEV with platelets, washed platelets
(8x108/mL) were incubated with a pooled sample (n = 3) of N STBEV (50μg/mL) or a Tyrodes-
HEPES control. Platelets were then fixed in 4% glutaraldehyde/PBS at 5sec (baseline) and at
1hr time points before centrifuging to pellet the fixed platelets (5000 xg for 5min) and routine
processing for transmission electron microscopy (TEM). Samples were post-fixed in 2%
osmium tetroxide in 0.1M phosphate buffer, followed by dehydration in ethanol and treatment
with propylene oxide prior to embedding in Spurr’s epoxy resin. Thin sections of suitable areas
were stained with uranyl acetate and lead citrate before examination using a Jeol 1200EX elec-
tron microscope.
Immunoblotting to Measure Platelet Total Tyrosine Phosphorylation
Washed platelets (n = 3 donors) were incubated with either Tyrodes-HEPES buffer, collagen
(0.1μg/mL), N STBEV (n = 3 individual preparations) or PE STBEV (n = 3 individual prepara-
tions) for 2min at 30°C. The incubation was stopped with the addition of 3x reducing loading
buffer (standard Laemmli recipe [22]) containing inhibitor cocktail. Immunoblotting was then
performed as described previously [23]. Briefly, samples were separated on 4–12% gradient
SDS-PAGE gels (NuPAGE; Invitrogen) and transferred onto PVDF membrane (Biorad) by
semi-dry transfer. Blots were probed for tyrosine phosphorylation using anti-phosphotyrosine
antibody (4G10, Upstate (Millipore)) followed by HRP-conjugated secondary antibody
(Dako). Bound antibodies were then detected using chemiluminescence substrate (Pierce Bio-
technology) and exposure to x-ray film (G.E.Healthcare). Band densities were quantified using
Image J software [Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with Image J. Bio-
photonics Int 2004;11:36e42], available from http://rsb.info.nih.gov/ij/.
Measurement of Platelet Aggregation in Response to STBEV
For aggregation assays, platelets were treated with either thrombin (0.5units/mL) or collagen
(0.1μg/mL; Nicomed) agonist, or N STBEV or PE STBEV (n = 3) at a final protein concentra-
tion of 50μg/mL, using Tyrodes-HEPES buffer as a control, at 30°C with continuous stirring
(1200 rpm) in an optical aggregometer. Platelets or PRP, that were pre-treated with STBEV
were incubated for 2min prior to the addition of an agonist or Tyrodes-HEPES control. Real
time changes in light transmission were logged using a chart recorder for at least 5 min.
In Vitro Thrombus Formation and Clot Retraction Assay
In vitro thrombus formation was carried out as described previously [24]. 3,3'-dihexyloxacar-
bocyanine iodide (DIOC6) labelled human citrated blood was pre-incubated for 1min with
Tyrodes-HEPES vehicle or with pooled N STBEV or PE STBEV (final protein concentration of
50μg/mL), prior to perfusion over a collagen coated Vena8 Biochip (Cylex Ltd, Ireland) at a
shear rate of 20 dynes/cm2 at 37°C. Z-stacked images of thrombi were obtained every 30sec for
10min using a Nikon eclipse (TE2000-U) microscope (Nikon instruments, UK). Fluorescence
intensity and thrombus volume were calculated using Slidebook5 software (Intelligent Imaging
Innovations, USA).
Clot retraction was measured by mixing human PRP (200μl), red blood cells prepared by
differential centrifugation (5μl) and STBEV (50μg/mL) from N STBEV (n = 3), PE STBEV
(n = 3) or Tyrodes-HEPES buffer alone. Clotting was initiated by thrombin (1U/mL) and a
glass capillary placed at the centre of the glass test tube. The weight of the resulting clots was
measured after 2hr and 4hr [25].
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Statistical Analysis
Thrombus formation data was analysed by post-hoc multiple comparison testing using a
2-way ANOVA with the Bonferroni correction in PRISM. All other data were analysed by stu-
dent t-tests. Results are presented as mean values ± standard error of the mean (mean±SEM).
P values of<0.05 were considered significant.
Results
Platelets and STBEV Associate and the Level of Association Is
Increased with Platelet Activation
Previous reports have suggested that STBEV carry bioactive tissue factor and that platelets
internalise tissue factor enriched vesicles [15] [26]. To determine whether STBEV obtained by
ex vivo dual placental perfusion associate with platelets (either by surface binding or uptake),
washed platelets were incubated with BODIPY-maleimide labelled STBEV and samples taken
at different time points and analysed by flow cytometry. The proportion of BODIPY-malei-
mide positive platelets increased from 21.9% (±0.6 S.E.) after 5sec (baseline) to 44.2% (±14.2 S.
E.) after 60min (Fig 1A). No increase in fluorescence was detected when using BODIPY-malei-
mide labelled STBEV alone, eliminating the possibility that fluorescent STBEV aggregates were
contributing to the signal from the platelet gate. Treatment with thrombin (0.5units/mL)
resulted in an additional increase in BODIPY-maleimide labelled STBEV positive events when
compared to resting platelets (from 22.2% (±4.3 S.E) at baseline to 48.5% (±15.3 S.E) at 5min
and 80.5% (±10.5 S.E.) after 60min (p = 0.0027 compared to resting at 60min)) (Fig 1A).
To investigate whether STBEV associate with the surface of platelets or are internalised,
electron microscopy was carried out on resting platelets, and following incubation with STBEV
for 5sec and 1hr (Fig 1B). The resulting images suggest that STBEV rapidly associate with
platelets and are internalised over time, with concomitant degranulation (Fig 1C–1E).
Platelet Activation Is Increased by Incubation with STBEV
To determine the effect of N STBEV and PE STBEV on platelet activation, total tyrosine phos-
phorylation in washed platelets incubated with normal or PE STBEV was examined. A signifi-
cant increase in platelet tyrosine phosphorylation was seen in response to PE STBEV (p<0.05),
the protein profile is similar to that caused by collagen stimulation although the intensity of
specific bands is altered (Fig 2A). No effect of N STBEV on platelet tyrosine phosphorylation
was evident (Fig 2A).
STBEV Cause Reversible Aggregation at High Platelet Concentrations
Previous reports had shown that PE STBEV have higher surface expression of tissue factor and
placental tissue factor causes platelet activation at high platelet concentrations [15] [26]. To
assess the response of platelets to STBEV produced by the dual perfusion method, aggregation
assays were performed in the presence and absence of STBEV using platelets at a concentration
of 8x108 /mL. Platelets did not aggregate when incubated with N STBEV, but reversible aggre-
gation was induced by PE STBEV (Fig 2B). Visual inspection of the samples following the
assay confirmed that no large visible aggregates remained. Aggregation was not observed in
response to STBEV at a platelet concentration of 4×108/mL (data not shown). This is typical of
weak platelet stimulation in which substantial levels of secretion are not observed.
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Fig 1. Platelets and STBEV association increases over time and with platelet activation.Washed platelets from 3 healthy donors were mixed with
BODIPYmaleimide-labelled STBEV in the presence of 0.5units ml/mL thrombin or Tyrodes-HEPES buffer control. Incubation was stopped at 5sec, 90sec,
5min, 20min and 60min followed by labelling for CD41 (platelet marker) and CD63 (platelet activation marker). A platelet gate was set to collect 10,000 events
and the percentage of BODIPYmaleimide-FITC positive events in the platelet gate recorded. (A) BODIPYmaleimide-FITC positive events in the platelet gate
showed STBEV binding by platelets that increases over time, with further increases in the presence of thrombin (*p = 0.043, **p = 0.0027). Black bars show
mean values. (B) Transmission electron microscopy of washed platelets incubated with STBEV for 5sec (i) and 1hr (ii-iv). The normal ultrastructure of resting
platelets can be seen at 5 sec (i).By 1 hour (ii) degranulated platelets were present that contained intra-cellular aggregates of putative STBEV (shown by
arrows and enlarged in iii). Phagocytosis of vesicular material was also evident (iv). Bars represent 1μm (i, ii) and 200nm (iii, iv).
doi:10.1371/journal.pone.0142538.g001
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Normal and PE STBEV Affect Rate of Clot Retraction
The latter stages of thrombus formation involve clot retraction which is driven by a contraction
of the platelet cytoskeleton and extracellular matrix and is co-ordinated through integrin
αIIbβ3 signalling. Incubation with N STBEV and PE STBEV caused a small but significant
decrease in clot size at 2hr (p<0.05; Fig 2C) but this effect was no longer apparent by 4hr, with
no significant difference between N STBEV or PE STBEV and Tyrodes-HEPES buffer control.
Agonist Induced Aggregation Is Attenuated by Incubation with STBEV
The effect of STBEV pre-treatment on agonist-induced aggregation was examined in washed
platelets (4×108/mL) and platelet rich plasma (PRP). A significant decrease in platelet
Fig 2. Platelet activation is increased by incubation with PE STBEV and aggregation and clot retraction are affected. (Ai and ii) Washed platelets
(n = 3 donors) were exposed to placental perfusion derived STBEV from healthy (N STBEV; n = 3) and pre-eclamptic (PE STBEV) pregnancies for 90sec.
Samples were separated by SDS-PAGE and immunoblotted for tyrosine phosphorylation. (Bi (representative experiment) and ii) Aggregation of washed
human platelets (n = 3) at 8x108/ml was measured in the presence of collagen (0.1μg/ml), N STBEV (n = 3) or PE STBEV (n = 3) over 5min. (C) Clot
retraction (n = 11 blood donors) in the presence of N STBEV (3 different placental donors), PE STBEV (3 different placental donors) or a Tyrodes-HEPES
control. Clots were weighed after 2hr. Black bars showmean values and * p< 0.05.
doi:10.1371/journal.pone.0142538.g002
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aggregation, in response to collagen, was observed at 90sec, 3min and 5min for both washed
platelets and PRP following pre-treatment (2 min) with STBEV (Fig 3A and 3C). The observed
decrease was significantly greater in response to PE STBEV compared to N STBEV (Fig 3A
and 3C) (P!0.05 at 5min following addition of collagen). The presence of plasma components
such as the clotting factors did not rescue aggregation (Fig 3C). A similar response to collagen
was seen following incubation with STBEV for 20min (data not shown) and a similar, but
much less pronounced trend was seen with thrombin treatment (0.5units/ml)(Fig 3B). This
suggests that this could be agonist specific effect though a full dose response would be required
to determine this.
Fig 3. STBEV attenuate platelet aggregation in response to collagen and thrombin. Representative aggregation traces and combined percentage
aggregation plots of (A) washed platelets preincubated with N STBEV, PE STBEV or Tyrodes-HEPES buffer (2 min) then stimulated with collagen (final
concentration 1μg/mL), (B) washed platelets preincubated with N STBEV, PE STBEV or Tyrodes-HEPES buffer then challenged with thrombin and (C)
Platelet rich plasma preincubated with N STBEV, PE STBEV or Tyrodes-HEPES buffer and then stimulated with collagen at a final concentration of 1 μg/mL.
In each case aggregation was followed for 5 min and the distance travelled on the chart recorder (mm) plotted from 3 replicate experiments where each
platelet preparation was exposed to 3 different PE STBEV and N STBEV preparations. Black bars represent mean values and *P < 0.05.
doi:10.1371/journal.pone.0142538.g003
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Aspirin Abrogates STBEV-Induced Aggregation
Prophylactic aspirin has been shown to reduce the relative risk of PE [17]. To investigate the
effect of aspirin on the PE STBEV-induced changes to aggregation observed above, PE STBEV
were added to aspirin-treated or non-aspirin-treated washed human platelets at 8x108/mL.
Aspirin treatment completely blocked PE STBEV-induced aggregation (Fig 4).
Fig 4. Aspirin treatment abolishes platelet aggregation in response to PE STBEV. Platelet rich plasma was incubated with 100 μM acetylsalicylic acid
(aspirin) or DMSO control for 30 minutes at 37°C. Platelets were then isolated and stimulated with thrombin, or PE STBEV (final concentration of 50μg/mL) at
37°C with continuous stirring (1200 rpm) in an optical aggregometer. Aggregation was observed over 5 min. (A) Representative aggregation traces and (B)
plot of aggregation replicates (n = 3 individual platelet preparations) * P!0.05 **!0.01
doi:10.1371/journal.pone.0142538.g004
STBEV Effect on Platelet Function
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Thrombus Formation Increases with STBEV
To assess the effects of STBEV on platelet activity under more physiologically relevant condi-
tions, thrombus formation in response to collagen was measured under flow. Overall, an
increase in the rate of thrombus formation was observed in the presence of STBEV with PE
STBEV showing a significantly increased rate of thrombus formation. No effect was seen in
response to the addition of N STBEV (Fig 5).
Discussion
Previous work has shown that platelet reactivity is increased in women who develop PE [13]
and that the placenta sheds increased amounts of STBEV, with altered phenotype and cargo,
Fig 5. STBEV increase thrombus formation.Whole blood mixed with the lipophilic dye 3,3-dihexyloxacarbocyanine iodide was treated with N STBEV, PE
STBEV or Tyrodes-HEPES control and perfused through collagen-coated (400 μg/mL) Vena8Biochip at a shear rate of 20 dyn/cm2. Thrombi were recorded
through a series of images in the Z-plane through their full depth every 30sec using a Nikon eclipse (TE2000-U) microscope, thrombus fluorescence intensity
was calculated using Slidebook, Version 5. The data represent thrombus volume (A) and sum fluorescence (B) (total fluorescence) intensities and are the
mean of 3 separate experiments on different blood donors. A post-hoc 2-way ANOVA with Bonferroni correction showed no significant difference between
control and N STB EV, the rate of thrombus formation (rate of change) (C and D) was increased in PE STBEV vs control (*P!0.05, ***P!0.001,
****P!0.0001) though there was no difference in the final thrombus size at 10 min. (E) 3D rendered images of thrombi formed under each experimental
condition.
doi:10.1371/journal.pone.0142538.g005
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into the maternal circulation during PE [10, 11]. Our aim was to provide a better understand-
ing of the role, if any, of STBEV in PE-associated changes in platelet reactivity.
This study shows that STBEV interact with platelets and affect their function. Flow cytome-
try revealed an interaction between platelets and STBEV that increased when platelets were
activated with thrombin, suggesting low levels of STBEV may bind platelets in normal preg-
nancy, whereas in the pro-coagulant environment of PE, there may be a greater affinity of acti-
vated platelets for STBEV. Electron microscopy suggested a rapid association between STBEV
and platelets followed by internalisation within 1hr. This is in line with previous work showing
that tissue factor-enriched vesicles prepared commercially from placenta are rapidly taken up
by platelets [26]. Activation was also suggested in the TEM images by the degranulation of
platelets treated with STBEV.
Examination of the effect of STBEV on global tyrosine phosphorylation and platelet aggre-
gation showed that exposure to PE STBEV increased platelet activation. No effect on activation
was seen in response to N STBEV. Platelets and STBEV are considered to be ‘sticky’; a property
that could, in theory, explain some of the observations. However, the clear differences in plate-
let response to STBEV from healthy and PE pregnancies strongly suggest that this is a mecha-
nistic effect rather than a simple association between ‘sticky’ entities. Interestingly, and in
agreement with previous findings [26], at high platelet concentrations, STBEV cause spontane-
ous reversible platelet aggregation, an effect that was dependent on platelet concentration
(8x108/ml) and unique to PE STBEV. The mechanism/s involved are currently under investiga-
tion, as is the suitability of the in vitro aggregation system, where exposure to STBEV is acute
and components can become rate limiting, to model the in-vivo situation where active constitu-
ents can be continually replenished and exposure to STBEV is over a much longer time frame.
Clot retraction in the presence of N STBEV and PE STBEV revealed a small overall increase in
the rate of clot retraction at 2hrs, suggesting that N STBEV and PE STBEV accelerate, but do
not enhance or inhibit, overall clot retraction to the same degree.
To determine whether the presence of STBEV affects normal platelet responses to known
agonists, washed platelets and platelet-rich plasma were challenged with collagen or thrombin
following pre-treatment with STBEV. Aggregation was reduced in both the washed platelets
and PRP in response to collagen and thrombin. Although it is possible that STBEV can steri-
cally inhibit aggregation, the fact that PE STBEV have a greater inhibitory effect than those
from normal placentas again suggests a qualitative effect, rather than STBEV just physically
blocking platelet-platelet interactions. This is in line with previous work that showed ADP-
stimulated aggregation was reduced in response to incubation with placental brush border
membrane vesicles, potentially due to an inhibition of thromboxane A2 [27, 28]. A decrease in
agonist-induced platelet aggregation appears contradictory to our observations that STBEV
promote activation and spontaneous aggregation. Currently we can only speculate on possible
mechanisms underlying this observation, such as the initial activation and internalisation of
STBEV potentially altering platelet plasma membrane composition or receptor trafficking such
that platelets are desensitised to subsequent challenges.
We found that aspirin (100 μM), at concentrations similar to that in patients on standard
doses (30–100 mg/L equivalent to 200–600 μM), abolished the aggregation effects caused by
STBEV interaction with platelets in vitro. This suggests that aspirin may confer some of its clin-
ical benefit by blocking STBEV driven platelet aggregation in vivo. Aspirin treatment is known
to reduce the effect of platelet agonists through the inhibition of cyclooxygenase 1 activity and
subsequent thromboxane A2 generation [29]. The observation that aspirin inhibits PE STBEV
stimulated aggregation suggests that these EV require activation of platelet signalling to pro-
mote aggregation, and do not simply agglutinate platelets. This may, in part, explain the mech-
anism by which low-dose aspirin reduces the CV complications and development of PE. The
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involvement of the second messenger thromboxane A2 in STBEV-mediated effects and the
potential alterations in cell surface composition following STBEV exposure will require further
investigation.
Thrombus formation was investigated in vitro. Our results show that PE STBEV increase
the rate of thrombus formation in whole blood under flow conditions (P!0.05 at 3–4 minutes)
therefore the size of thrombus formed is also increased (P! 0.05 at 3–6.5 minutes). There was
a high degree of variability between donors not usually seen with this technique, which may
indicate some individuals are more susceptible than others to the effects of STBEV, and may be
in line with the variability of pathology in PE patients.
The concentration of STBEV used here was 50μg/ml, which is higher than previously found
in the maternal bloodstream (e.g. 26 ng/mL in healthy pregnancy, 42 ng/mL in late onset PE
and 71 ng/mL in early onset forms of the disease [30] however, it is likely that local concentra-
tions will vary, especially at areas of STBEV release and reduced flow in the intervillous space
of the placenta. STBEV have been detected in the circulation as early as the first trimester [10,
31]. In general, STBEV from patients with PE had a greater effect on platelet function and acti-
vation, suggesting that STBEV could contribute to the thrombotic pathology of PE. If a causa-
tive role for STBEV in PE can be established, and relevant activation pathways identified, this
would facilitate interventions to block platelet-STBEV binding, or the affected pathways to be
targeted. It should be noted that the size and rate of release of STBEV is increased in PE [7, 9],
however for this work STBEV samples were normalised for protein concentration. Therefore,
the difference between healthy pregnancy and PE in vivomay be even more pronounced.
Microvesicles and exosomes are produced via distinct mechanisms from the STB and have
different compositions and functions [32]. Exosomes are produced in the endosomal compart-
ment through the production of multivesicular bodies and are constitutively secreted by the
STB [8, 11]. They possess a distinct profile of proteins including pro-apoptotic proteins and
TGFβ and are immunosuppressive [33]. Microvesicles on the other hand are pro-inflammatory
and may have beneficial local effects during the early stages of normal pregnancy by increasing
STB exosome production, as cellular stress has been shown to drive exosome production in
other cell types [34]. It has previously been demonstrated that there is a higher level of EV pro-
duction in PE and that the vesicles produced are larger in size [7–9]. During healthy pregnancy,
a ratio between microvesicles and exosomes may be maintained that allows for sustained low-
level inflammation that drives exosome production. If the ratio were disturbed, by poor placen-
tal perfusion and the resultant trophoblast oxidative and ER stress, this could lead to the exces-
sive production of pro-inflammatory, procoagulant and anti-angiogenic microvesicles, effects
that are central to the pathology of PE. Perturbation of the microvesicle-exosome ratio and dif-
ference in STBEV composition may also explain the heterogeneity in maternal symptoms and
could provide an explanation for the divergent effects on platelets of N STBEV and PE STBEV
described here.
This work has provided new insight into the role of STBEV in the platelet dysfunction asso-
ciated with the multifactorial and multisystem condition of PE.
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